ANKEBIO
Biopharmaceutical R&D and Manufacturer
BoAn Biotech
Integrated Biopharmaceutical R&D and Manufacturing Company
Regeneron
Biopharmaceutical Manufacturer
2026Year4Month2Anhui Anke Biotechnology (Group) Co., Ltd. Announces Major Personnel AppointmentDr. Changlin Dou, an internationally renowned biopharmaceutical innovation expert and former Chief Operating Officer and Head of R&D at Shandong BoAn Biotechnology Co. Ltd., has officially joined the company as its Chief Executive Officer and Chief Scientist.Comprehensively steer the establishment of R&D systems, the construction of cutting-edge technology platforms, and global layout, propelling the company towards becoming a globally leading innovative pharmaceutical enterprise.
Public information shows that Dr. Dou Changlin,1963Born in the year, American nationality, a senior expert in the global biopharmaceutical field, and also the core founder of BoAn Biotechnology. He1984Year7Received a Bachelor of Biology from Peking University in the month of [specific month].1988Year3Received a master's degree from the Institute of Neuroscience, Chinese Academy of Sciences in ...1995Received a Ph.D. from Stony Brook University, State University of New York, in the year, and worked at Regeneron-Completed postdoctoral research at the Caitlin Cancer Center.
1995Year to2013During the years, Dou Changlin successively worked in the United States.Regeneron, Genentech,InvitrogenAmong several top global biopharmaceutical institutions, he has served as a senior scientist, team leader, and other roles, leading the research and development of antibody drugs, high-expression technology, and process development. During this period, he obtained multiple U.S. patents as an inventor, and his R&D achievements have been applied in various globally marketed drugs.
2012Year, he in Shandong Province“Taishan Scholar Overseas Distinguished Expert”Return to China,2013Year12Joined BoAn Biotechnology in [Month], responsible for the early establishment of the company and the construction of the technology platform. Later, he served as the President of R&D, Chief Operating Officer, Executive Director, and Chairman of the Strategy Committee, fully leading the company's R&D strategy, pipeline development, and...CMCSystem Construction, Successfully Promoting BoYouNuo and others3The antibody drug has been launched in China, and led by9Products have entered clinical stages in China, the US, Europe, and Japan.
2026Year3Month31Dou Changlin resigned from all positions at Shandong BoAn Biotechnology Co. Ltd. upon reaching the statutory retirement age.
In terms of compensation, according to the publicly disclosed information from BoAn Biotechnology, his annual remuneration during his term of office was722.40RMB 10,000.
20264Month, joined ANKEBIO as Chief Executive Officer and Chief Scientist.
